{
  "company": {
    "name": "Confo Therapeutics",
    "website": "https://confotherapeutics.com/",
    "record": "https://startuphistory.org/c/confotherapeutics.com"
  },
  "status": null,
  "history_since": "2025-07-22T20:18:14.000Z",
  "baseline": {
    "snapshot_id": "0d76cd09cb18825b4ca018b0dfee7bfb5fb81dbc6025bda661c1e074eada2d17",
    "observed_at": "2025-07-22T20:18:14.000Z",
    "headline": "Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases",
    "description": "Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.",
    "evidence": "https://web.archive.org/web/20250722201814/https://www.confotherapeutics.com/",
    "evidence_kind": "internet_archive",
    "facts": {
      "version": 1,
      "pages": [
        {
          "page": "home",
          "customers": [],
          "investors": [],
          "prices": [],
          "compliance": [],
          "funding": [
            "Confo Therapeutics Announces EUR 60M Series B Financing to Advance a Pipeline of Novel GPCR-Modulating Therapies into Clinical Development Press release"
          ]
        }
      ]
    },
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T12:55:34.010Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2026-11-05T12:55:34.010Z",
      "variants": [
        {
          "headline": "Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases",
          "subhead": "Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.",
          "observed_at": "2025-07-22T20:18:14.000Z",
          "evidence": "https://web.archive.org/web/20250722201814/https://www.confotherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases",
          "subhead": "Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.",
          "observed_at": "2026-04-30T16:40:37.000Z",
          "evidence": "https://web.archive.org/web/20260430164037/https://www.confotherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases",
          "subhead": "Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.",
          "observed_at": "2026-07-11T20:34:16.000Z",
          "evidence": "https://web.archive.org/web/20260711203416/https://www.confotherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases",
          "subhead": "Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.",
          "observed_at": "2026-11-05T12:55:34.010Z",
          "evidence": "https://www.confotherapeutics.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases",
      "subhead": "Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.",
      "from": "2025-07-22T20:18:14.000Z",
      "to": "2026-11-05T12:55:34.010Z",
      "captures": 4,
      "evidence": "https://www.confotherapeutics.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2025-07-22T20:18:14.000Z",
          "to": "2026-11-05T12:55:34.010Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-0d76cd09cb18825b4ca018b0dfee7bfb5fb81dbc6025bda661c1e074eada2d17:89648a3361cd03c8fd9734e8458a14a790dbb1380d03f367bbb9a067c9592860:funding:8a9a5acc131203b4",
      "before_evidence": "https://web.archive.org/web/20250722201814/https://www.confotherapeutics.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “Confo Therapeutics Announces EUR 60M Series B Financing to Advance a Pipeline of Novel GPCR-Modulating Therapies into Clinical Developmen…”.",
      "between": {
        "from": "2025-07-22T20:18:14.000Z",
        "to": "2026-04-30T16:40:37.000Z"
      },
      "evidence": "https://web.archive.org/web/20260430164037/https://www.confotherapeutics.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Confo Therapeutics” company record, https://startuphistory.org/c/confotherapeutics.com"
}